

Bladder pain syndrome: Evolving strategies

Poster Session 34

Sunday, 13 March
12:15 - 13:45

Location: Room 14a (ICM, Level 1)

Chairs: P. Dinis Oliveira, Porto (PT)
D.S. Engeler, St. Gallen (CH)
H-C. Kuo, Hualien (TW)

Aims and objectives of this presentation

New and old treatment options

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

- *418 **Immunotherapy to treat bladder painful syndrome**
By: Augé C.², Lluet P.², Vergnolle N.¹, Dietrich G.¹
Institutes:¹Purpan Hospital, Inserm Umr1043, Toulouse, France, ²UROsphere, Dept. of Pharmacology, Toulouse, France
- *419 **Toll like receptor 7 is overexpressed in the bladder mucosa of Hunner type interstitial cystitis and its activation in the mouse bladder induces cystitis and pain**
By: Ichihara K.¹, Aizawa N.¹, Sugiyama R.¹, Ito H.¹, Kamei J.¹, Akiyama Y.¹, Masumori N.², Andersson K-E.⁴, Homma Y.³, Igawa Y.¹
Institutes:¹The University of Tokyo Graduate School of Medicine, Dept. of Continence Medicine, Tokyo, Japan, ²Sapporo Medical University School of Medicine, Dept. of Urology, Sapporo, Japan, ³The University of Tokyo Graduate School of Medicine, Dept. of Urology, Tokyo, Japan, ⁴Aarhus University, Aarhus Institute of Advanced Studies, Aarhus, Denmark
- *420 **Development and validation of a clinically-relevant chronic model of interstitial cystitis/bladder painful syndrome**
By: Chabot S.¹, Augé C.¹, Meen M.¹, Guilloteau V.¹, Vergnolle N.², Gamé X.³, Lluet P.¹
Institutes:¹Urosphere, Dept. of Urology, Toulouse, France, ²INSERM UMR1043, Purpan University Hospital, Toulouse, France, ³INSERM I2MC-U1048, Rangueil University Hospital, Dept. of Urology, Toulouse, France
- *421 **Comparison of Cystistat®, iAluril®, and Whitmore Cocktail for treatment of patients with bladder pain syndrome/interstitial cystitis**
By: Cocci A.¹, Alowidah I.², Skews R.², Hashim H.²
Institutes:¹University of Florence, Dept. of Urology, Florence, Italy, ²Bristol Urological Institute, Dept. of Urology, Bristol, United Kingdom
- *422 **Pelvic inflammatory disease is associated with bladder pain syndrome/interstitial cystitis: A population-based case-control study**
By: Tan J-S.
Institutes:Far Eastern Memorial Hospital, Dept. of Urology, New Taipei City, Taiwan
- *423 **The effect of intravesical liposome-based NGF antisense therapy on bladder overactivity and nociception in a rat model of cystitis induced by hydrogen peroxide**
By: Majima T.¹, Tyagi P.², Dogishi K.³, Kashyap M.², Gotoh M.¹, Chancellor M.B.⁴, Yoshimura N.²
Institutes:¹Nagoya University School of Medicine, Dept. of Urology, Nagoya, Japan, ²University of Pittsburgh, Dept. of Urology, Pittsburgh, United States of America, ³University of Kyoto, Dept. of Molecular Pharmacology, Kyoto, Japan, ⁴Oakland University William Beaumont School of

Medicine, Dept. of Urology, Royal Oak, United States of America

*424 **Chronic pelvic pain syndrome is similar as features and symptoms of occlusive lesions of common and internal iliac arteries**

By: Belousov I., [Kogan M.I.](#)

Institutes:Rostov State Medical University, Dept. of Urology, Rostov on Don, Russia

*425 **Analysis of multiple urine markers for the detection of interstitial cystitis/bladder pain syndrome in patients with lower urinary tract symptoms**

By: [Furuta A.](#)¹, Yamamoto T.², Koike Y.¹, Suzuki Y.³, Gotoh M.², Egawa S.⁴, Yoshimura N.⁵

Institutes:¹Jikei University School Of Medicine, Dept. of Urology, Tokyo, Japan, ²Nagoya University Graduate School of Medicine, Dept. of Urology, Nagoya, Japan, ³Tokyo Metropolitan Rehabilitation Hospital, Dept. of Urology, Tokyo, Japan, ⁴Jikei University School of Medicine, Dept. of Urology, Tokyo, Japan, ⁵University of Pittsburgh School of Medicine, Dept. of Urology, Pennsylvania, United States of America

*426 **Possible role of matrix metalloproteinase-8 in pathophysiology of interstitial cystitis/painful bladder syndrome**

By: [Piecha T.](#)¹, Poletajew S.¹, Wyczałowska-Tomasik A.², Gala K.², Burdzińska A.², Piątek L.², Radziszewski P.¹

Institutes:¹Medical University of Warsaw, Dept. of General, Oncological and Functional Urology, Warsaw, Poland, ²Medical University of Warsaw, Dept. of Immunology, Transplantation and Internal Diseases, Warsaw, Poland

*427 **Plasma and urinary pharmacokinetics of the novel, oral SHIP1 activator, AQX-1125 in interstitial cystitis/bladder pain syndrome (IC/BPS): Results of the phase2 LEADERSHIP trial**

By: Nickel C.², Evans R.³, Tam P.⁴, Toews J.⁴, MacKenzie L.⁴, Biagi H.¹, [Shrewsbury S.](#)¹

Institutes:¹Aquinox Pharmaceuticals, Dept. of Clinical Development, Vancouver, Canada, ²Queen's University, Dept. of Urology, Kingston, Canada, ³Wake Forest University Health Sciences, Dept. of Urology, Winston Salem, United States of America, ⁴Aquinox Pharmaceuticals, Dept. of Technical Operations, Vancouver, Canada

*429 **5-HT in the rat prefrontal cortex controls the micturition reflex via 5-HT_{2A} and 5-HT₇**

By: [Hiroki C.](#)¹, Mitsui T.², Kitta T.¹, Ohmura Y.³, Moriya K.¹, Kanno Y.¹, Yoshioka M.³, Shinohara N.¹

Institutes:¹Hokkaido University, Dept. of Urology, Sapporo, Japan, ²Yamanashi University, Dept. of Urology, Yamanashi, Japan, ³Hokkaido University, Dept. of Neuropharmacology, Sapporo, Japan

13:30 - 13:37

Summary and context

P. Dinis Oliveira, Porto (PT)